Literature DB >> 8832257

Premenstrual dysphoric disorder. An update.

M Steiner1.   

Abstract

The recent inclusion of research criteria for premenstrual dysphoric disorder (PMDD) in the DSM-IV should help physicians recognize women with symptoms of irritability, tension, dysphoria, and lability of mood which seriously interfere with their lifestyle. PMDD can be differentiated from premenstrual syndrome (PMS) which is primarily reserved for milder physical symptoms and minor mood changes. The use of DSM-IV criteria in conjunction with prospective daily charting for at least two cycles is now accepted as common practice in confirming the diagnosis. Treatment options range from conservative lifestyle and stress management to treatment with psychotropic medications and hormonal or surgical interventions to eliminate ovulation for the more extreme cases. Results from several randomized placebo-controlled trials have clearly demonstrated that selective serotonin reuptake inhibitors as well as medical or surgical oophorectomy are very effective in treating PMDD. Taken together, these data indicate that treatment may be accomplished by either eliminating the hormonal trigger or by reversing the sensitivity of the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8832257     DOI: 10.1016/0163-8343(96)00044-8

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  2 in total

1.  Is sertraline an effective therapy for premenstrual dysphoric disorder?

Authors:  O Fernandes; C P Por; M F Evans
Journal:  Can Fam Physician       Date:  1998-04       Impact factor: 3.275

Review 2.  Ovarian steroids and serotonin neural function.

Authors:  C L Bethea; M Pecins-Thompson; W E Schutzer; C Gundlah; Z N Lu
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.